<DOC>
	<DOC>NCT00419146</DOC>
	<brief_summary>The purpose of this trial is to study the effect of adding the omega-3 fatty acid EPA and/or Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related psychoses.</brief_summary>
	<brief_title>Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants</brief_title>
	<detailed_description>Objective: Study the effect of adding Ethyl-EPA and/or Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related psychoses. Methods and material: - Design: Multicentre, randomized, double-blind, placebo-controlled, fixed dose, 2x2 factorial, add-on clinical trial. - Sample: - Patients with schizophrenia, schizoaffective disorder or schizophreniform disorder (DSM-IV); aged 18-40 years; less than 15 years since first psychotic symptoms;admitted to a psychiatric department within the previous 21 days before screening; speaks fluently a Scandinavian language;treated with antipsychotics; written informed consent;no known allergy to trial agents;no substance dependence (DSM-IV);no warfarin currently or anamnestic indicators of impaired haemostasis. Planned: 200 patients. Actually included: 99 intent-to-treat patients. - Healthy controls: aged 18-40 years;no mental disorder (DSM-IV). Included: 20 persons. - Clinical assessments: Positive and Negative Syndrome Scale (PANSS) (main outcome variable). Self-report questionnaire. Adverse effects (UKURS). Neurocognitive assessment battery. Niacin skin flush test. General medical assessment. - Blood samples: RBC fatty acids, S-Î±-tocopherol, F2-isoprostane (kits), monocyte mRNA Phospholipase A22 (PLA2) Gr4a and 6a (RT-PCR method), RBC Gr4a PLA2 concentration (ELISA technique), a range of other biochemical tests. - Experimental treatment over 16 weeks: Ethyl-EPA 2 g/d or Placebo EPA and Vitamin E 364 mg/d + Vitamin C 1000 mg/d or Placebo Antioxidants - Statistics: Linear Mixed Model for longitudinal analyses of effects; other uni- and multivariate methods (SPSS 12.0 - PASW Statistics 18).</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>Patients with schizophrenia, schizophreniform disorder or schizoaffective disorder (DSMIV) Admitted to a psychiatric hospital/department within the previous twentyone days before screening Less than fifteen years, in retrospect, since first psychotic symptoms (DSMIV 295, criteria A,14) Age 1840 years Speaks fluently a Scandinavian language A written informed consent must be obtained before any trialrelated activities A diagnosis of substance dependence (DSMIV) Known allergy to study medication Currently taking warfarin or having anamnestic indicators of impaired haemostasis (profuse bleeding, except epistaxis)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophreniform disorders</keyword>
	<keyword>Schizoaffective disorder</keyword>
	<keyword>Psychotic disorders</keyword>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>Longitudinal Studies</keyword>
	<keyword>Fatty Acids, Omega-3</keyword>
	<keyword>Eicosapentaenoic Acid</keyword>
	<keyword>Vitamins</keyword>
	<keyword>Antioxidants</keyword>
	<keyword>Ascorbic Acid</keyword>
	<keyword>Alpha-Tocopherol</keyword>
	<keyword>Placebos</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Oxidative Stress</keyword>
	<keyword>Fatty Acids, Unsaturated</keyword>
	<keyword>Phospholipases</keyword>
	<keyword>Niacin</keyword>
	<keyword>Adverse effects</keyword>
	<keyword>Delusions</keyword>
	<keyword>Hallucinations</keyword>
	<keyword>Neuropsychological Tests</keyword>
	<keyword>Attention</keyword>
	<keyword>Memory</keyword>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>Models, Statistical</keyword>
</DOC>